The FDA has recently announced a groundbreaking expansion in the approval of Eli Lilly’s obesity drug, Zepbound, now also sanctioned for treating moderate to severe obstructive sleep apnea in individuals grappling with obesity.
The FDA has recently announced a groundbreaking expansion in the approval of Eli Lilly’s obesity drug, Zepbound, now also sanctioned for treating moderate to severe obstructive sleep apnea in individuals grappling with obesity.